Final 3 year results from the landmark HORIZONS-AMI trial published in the Lancet
June 13, 2011 in CardiologyData from the landmark HORIZONS-AMI clinical trial demonstrated that the administration of the anticoagulant medication bivalirudin enhanced survival compared to the use of heparin plus a glycoprotein (GP) IIb/IIIa inhibitor in heart attack patients undergoing angioplasty after 3 years. Use of a drug-eluting stent (paclitaxel) was also shown to be more effective than a bare-metal stent, with equivalent safety. Final 3-year results of the trial were published in the June 13, 2011, issue of The Lancet.
After 3 years, treatment with bivalirudin alone compared to heparin plus a GP IIb/IIIa inhibitor resulted in significantly reduced rates of all-cause mortality (5.9% vs. 7.7%), cardiac mortality (2.9% vs. 5.1%), reinfarction (6.2% vs. 8.2%) and major bleeding not related to bypass graft surgery (6.9% vs. 10.5%). There were no significant differences in the incidence of ischemia-driven target vessel revascularization, stent thrombosis, stroke, or composite adverse events.
In addition, at 3 years, the implantation of a paclitaxel-eluting stent compared to a bare-metal stent resulted in significantly lower rates of ischemia-driven target lesion revascularization (9.4% vs. 15.1%) with no significant differences in the rates of death, reinfarction, stroke, or stent thrombosis.
"The results at 3 years demonstrate that use of bivalirudin alone, as opposed to a combination of heparin and a GP IIb/IIIa inhibitor, can save lives. The reported reduction in all-cause mortality seen in the trial equates to 18 lives saved per 1,000 patients treated with bivalirudin," said Gregg W. Stone, MD, Professor of Medicine at Columbia University College of Physicians and Surgeons, Director of Cardiovascular Research and Education at the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital/Columbia University Medical Center and Co-Director of the Medical Research and Education Division at the Cardiovascular Research Foundation (CRF). Dr. Stone is the principal investigator of the HORIZONS-AMI trial.
"Additionally, results of the trial showed that patients who received a paclitaxel-eluting stent had a 40% reduction in risk of ischemia-driven target lesion revascularization after 3 years compared with those patients given a bare-metal stent," Dr. Stone said.
While previous studies of drug-eluting stents have often focused on their use in patients with stable or unstable chest pain, this is the largest study to focus on the appropriate use of anticoagulation medications and drug-eluting stents in patients experiencing the most dangerous form of heart attack (ST-elevation myocardial infarction).
Sponsored by the Cardiovascular Research Foundation, with research grant support from Boston Scientific Corporation and The Medicines Company, the HORIZONS AMI (Harmonizing Outcomes with RevascularIZatiON and Stents in Acute Myocardial Infarction) trial enrolled 3,602 patients presenting with a heart attack to hospitals in 11 countries. More than 120 national and international interventional cardiology centers participated in the trial.
Three-year results of the trial were first reported at the 2010 Transcatheter Cardiovascular Therapeutics (TCT) annual scientific symposium, sponsored by CRF.
Provided by Cardiovascular Research Foundation
-
Drug-eluting stents better than bare-metal stents for heart attack patients
Sep 25, 2009 |
not rated yet |
0
-
Drug-eluting stents more effective than bare-metal stents in heart attack patients
May 26, 2009 |
not rated yet |
0
-
Study finds everolimus-eluting stent safer, more effective than paclitaxel-eluting stent
May 05, 2010 |
not rated yet |
0
-
Findings released from 1 of the largest percutaneous coronary intervention trials ever
May 23, 2008 |
not rated yet |
0
-
Drug-releasing stent shows promise for improving outcomes in patients with coronary artery disease
Apr 22, 2008 |
not rated yet |
0
-
Of mice and mental models: Neuroscientific implications of risk-optimized behavior in the mouse
1 hour ago |
not rated yet |
0
-
Limits to growth: Scientists identify key metastasis-enabling enzyme
May 22, 2012 |
5 / 5 (3) |
0
-
Seeing is as seeing does: Spatially-structured retinal input in early development of cortical maps
Apr 26, 2012 |
5 / 5 (4) |
1
-
Dreamless nights: Brain activity during nonrapid eye movement sleep
Apr 09, 2012 |
4.4 / 5 (12) |
0
-
Take your time: Neurobiology sheds light on the superiority of spaced vs. massed learning
Mar 28, 2012 |
4.5 / 5 (21) |
3
-
Work done on body moving in a circle
3 hours ago
-
Crest or Trough?
3 hours ago
-
Origin of magnetism
6 hours ago
-
Polarization vector of water molecule
9 hours ago
-
understanding the strain energy function invariant term
13 hours ago
-
a numerical problem...kindly provide d solution
22 hours ago
- More from Physics Forums - Classical Physics
More news stories
New study should end debate over magnesium treatment for preventing poor outcome after haemorrhagic stroke
An international randomised trial and meta-analysis published Online First in The Lancet should put an end to the debate about the use of intravenous magnesium sulphate to prevent poor outcomes after haemorrhagic stroke. The in ...
Cardiology
3 hours ago |
not rated yet |
0
Low vitamin D in diet increases stroke risk in Japanese-Americans
Japanese-American men who did not eat foods rich in vitamin D had a higher risk of stroke later in life, according to results of a 34-year study reported in Stroke, an American Heart Association journal.
Cardiology
18 hours ago |
not rated yet |
0
Clot buster seems to help up to 6 hours after stroke
(HealthDay) -- The largest study of its kind finds that stroke patients benefit from a clot-busting drug even six hours after a stroke, suggesting that the current recommended 4.5-hour limit could be expanded.
Cardiology
May 24, 2012 |
not rated yet |
0
Calcium supplements linked to significantly increased heart attack risk
Calcium supplements might increase the risk of having a heart attack, and should be "taken with caution," concludes research published in the online issue of the journal Heart.
Cardiology
May 23, 2012 |
not rated yet |
2
|
New study confirms value of cardiac output monitor
(Medical Xpress) -- A new Australian study has confirmed the accuracy of a modern non-invasive cardiac output monitor that can replace a 40-year-old standard in this field.
Cardiology
May 23, 2012 |
not rated yet |
0
Physicians definitively links irritable bowel syndrome and bacteria in gut
An overgrowth of bacteria in the gut has been definitively linked to Irritable Bowel Syndrome in the results of a new Cedars-Sinai study which used cultures from the small intestine. This is the first study to use this "gold ...
First study to suggest that the immune system may protect against Alzheimer's changes in humans
Recent work in mice suggested that the immune system is involved in removing beta-amyloid, the main Alzheimer's-causing substance in the brain. Researchers have now shown for the first time that this may apply in humans.
Phone contact with nurses linked with better outcomes for women with gestational diabetes
Among women with gestational diabetes mellitus, referral to a telephone-based nurse management program was associated with lower risk of high baby birth weight and increased postpartum glucose testing, according to Kaiser ...
Of mice and mental models: Neuroscientific implications of risk-optimized behavior in the mouse
(Medical Xpress) -- Regardless of an organism’s biological complexity, every encephalized animal continuously makes under-informed behavioral choices that can have serious consequences. Despite its ubiquity, ...
Questionable research practices surprisingly common
(Medical Xpress) -- Not all scientific misconduct is flat-out fraud. Much falls into the murkier realm of questionable research practices. A new study finds that in one field, psychology, these practices are surprisingly ...
Researchers identify key brain cell in antidepressant action
(Medical Xpress) -- Antidepressant medications such as Prozac have helped improve mood and lessen anxiety in millions of people with major depression. But scientists know surprisingly little about how these drugs work.